Background. Rubella is usually a mild rash illness. However, when a woman contracts rubella early in pregnancy, serious consequences may occur, including birth defects known as congenital rubella syndrome (CRS). Information is limited on the epidemiology of rubella and CRS in Ethiopia.
Rubella is usually a mild febrile rash illness in adults and children. However, when a pregnant woman becomes infected, particularly during the first trimester, serious consequences can occur, including a constellation of birth defects known as congenital rubella syndrome (CRS). The defects associated with CRS are ophthalmic (eg, cataracts, microphthalmia, glaucoma, and chorioretinitis), auditory (eg, sensorineural deafness), cardiac (eg, patent ductus arteriosus), and craniofacial. Infants with CRS who survive the neonatal period may face serious developmental disabilities (eg, visual and hearing impairment) and have an increased risk for developmental delay, including autism. Although little is known about rubella epidemiology and the incidence of CRS in Africa, it has been estimated that 110,000 CRS cases occur each year during nonepidemic years in developing countries [1] [2] [3] .
In 2008, the population of Ethiopia was estimated to be 77.6 million, with 83% living in rural areas. It is estimated that children ,5 years of age make up 12.5% of the population, and 90% of the population has access to formal health care services [2, 3] . Life expectancy at birth is estimated to be 55 years, and the total fertility rate is 5.3 children per woman of child bearing age. [4] The country has a surface area of 1.1 million square kilometers and is administratively divided into 9 regional States and 2 city administrations. There are .80 linguistic groups in Ethiopia.
The national Expanded Programme on Immunization (EPI) was established in 1980 in Ethiopia and includes provision of the first dose of measles-containing vaccine (MCV1) provided at or shortly after the ninth month of age [5] .
Rubella, and therefore CRS, can be prevented by vaccination. Rubella vaccination has not been introduced into the infant vaccination schedule in Ethiopia. In the major urban centers, some private practitioners provide rubella vaccination to infants at 9 months of age or older in the form of measles-rubella vaccine. However, these private sector vaccination services are not monitored, and the rubella vaccination coverage in the general population is unknown.
Surveillance for rubella or CRS does not exist in Ethiopia; however, the measles case-based surveillance system, established in 2004, includes laboratory testing for the detection of measlesspecific and rubella-specific antibodies. The measles case-based surveillance system has helped greatly in terms of documenting the epidemiology of measles in Ethiopia. However, little is known of the magnitude and distribution of other febrile rash illnesses. In African countries, including Ethiopia, CRS is widely under-recognized as a public health problem, and information on rubella and CRS epidemiology is very limited [5] . This article summarizes the results of rubella testing through the measles case-based surveillance system and provides an epidemiological description of the laboratory-confirmed rubella cases in Ethiopia during [2004] [2005] [2006] [2007] [2008] [2009] .
METHODS
In 2004, following surveillance guidelines from the World Health Organization (WHO) African Regional Office, a system of measles case-based surveillance was established in Ethiopia to monitor the impact of measles control activities [6] . In this surveillance system, a suspected measles case was defined as an illness in a person who presented with fever, generalized rash, and either cough, or coryza, or conjunctivitis. An individual with a suspected measles case who presented within 30 days of the onset of rash was investigated using a standardized individual case investigation form, and a serum specimen was collected for all suspected measles cases except for those that were epidemiologically linked to a confirmed measles outbreak. Serum specimens were sent to the national measles laboratory based in the Ethiopian Health and Nutrition Research Institute in Addis Ababa for laboratory testing using standard commercial indirect enzyme-linked immunosorbent assay (Enzygnost for IgM; Dade Behring) kits [7] . The national measles laboratory in Ethiopia was a member of the global World Health Organization (WHO) vaccine-preventable diseases laboratory network. The laboratory was subjected to periodic quality control exercises and had been accredited annually since 2004.
Specimens that tested positive for measles-specific immunoglobulin (Ig) M and were from patients who had not received measles vaccination within 4 weeks prior to the specimen collection were classified as indicating laboratory-confirmed measles. Serum samples that were determined to be measles IgM negative or that had 2 sets of indeterminate results for measles IgM were tested for rubella IgM antibody. Patients with rubella IgM-positive serum samples were classified as having laboratory-confirmed rubella cases. The laboratory results and completed individual case investigation forms were sent to the Federal Ministry of Health (FMoH), and the information was entered into an electronic database. The case-based surveillance data are regularly reported by the FMoH to the WHO country office. Data for this review were analyzed using EpiInfo 2000 and the SPSS statistical package (version 16).
RESULTS
From January 2004 through December 2009, a total of 11,857 suspected measles cases were investigated with blood specimen collection for confirmatory laboratory testing. Of these, 8212 (69%) were tested for rubella-specific IgM antibody according to laboratory procedures; however, in 2009, because of a shortage of measles and rubella IgM test kits, 600 serum samples were not tested. Of the 8212 cases tested, 992 (12%) were laboratory-confirmed as rubella, 6691 (81%) had test results that were negative for rubella IgM, and 529 (6%) had test results that were indeterminate (Table 1) . Specimens were collected within 14 days after rash onset for a total of 7832 (95%) of the 8212 specimens tested, including 936 (94%) of the rubella IgM-positive serum samples, in 6338 (95%) of the rubella IgM-negative serum samples, and 512 (97%) of the rubella IgM indeterminate serum samples.
During 2004-2009, rubella cases were reported from all 11 regions of Ethiopia, and cases were distributed widely throughout the country (Table 2 ). Seasonal distribution of cases occurred each year and peaked from March through June (Figure 1) .
The age distribution of the laboratory-confirmed rubella cases ranged from 3 months to 44 years (mean age, 6 years and 8 months; median age, 6 years). The majority (94.7%) of the cases were in individuals ,15 years of age, and 54% of the patients were female (Table 3) . [8, 9] . In both surveys, the prevalence of rubella seropositivity was found to be R94% among individuals R14 years of age. The seroprevalence study by Cutts et al [8] was conducted in Addis Ababa; the other seroprevalence survey included urban centers in 4 different regions and 1 district, and seroprevalence ranged from 85% to 97% [9] . In this series, 7220 (61%) of the 11,857 specimens from individuals with suspected measles cases had test results that were negative for measles IgM antibodies and later had negative or indeterminate rubella test results. One of the reasons for this may be the timing of the collection of the specimens. It is known that specimens collected within the first 3 days of the onset of measles rash or after 28 days may not have antibody levels high enough to be detected using the standard serological tests. However, according to the surveillance protocols, the collection of specimens is encouraged anytime within the first month after the onset of rash, so that opportunities for laboratory testing are not missed. Another possible reason is the presence of other febrile rash illnesses, such a chickenpox, erythema infectiosum, roseola infantum, meningococcal infections, scarlet fever, enteroviral infections, and drug rashes.
In a literature review of CRS and acquired rubella in developing countries, Cutts et al [10] reported that data from developing countries suggested that the risk of CRS is at least as high as that in industrialized countries during the prevaccination era. However, this review indicated the need for further information on the burden of CRS. In the study in Addis Ababa, CRS incidence was estimated at 0.3 cases per 1000 live births [8] . This finding is consistent with the incidence of CRS estimated at 0.1-0.2 cases per 1000 live births during the period of endemicity prior to vaccine introduction [2] .
These results are subject to several limitations. First, the case definition used to detect the rubella cases was designed for the measles case-based surveillance system and is specific for measles. Many individuals with rubella cases may not have any significant fever, and up to 50% of individuals with rubella cases may present without a rash or have subclinical illness. The sensitivity of this case definition is likely not high enough to identify all rubella cases.
The integration of rubella testing alongside measles casebased surveillance provides an opportunity to gain understanding about the epidemiology of rubella infection. Since 1999, countries in the American Region of the WHO have conducted integrated rubella and measles surveillance [11] . For purposes of integrated surveillance, a patient who presents with generalized rash and fever or is suspected by a health care worker of having measles or rubella infection is considered to have a suspected measles or rubella case [12] . The adoption of a case definition that is more sensitive for rubella, similar to the one used in Pan American Health Organization, would likely lead to an increase in case detection and a better understanding of the rubella epidemiology without losing sensitivity for detecting measles. To better understand the burden and epidemiology of rubella and CRS, Ethiopia may consider adopting a comprehensive approach to surveillance, including a more inclusive case definition for measles and rubella, establishing sentinel surveillance for CRS, and conducting appropriate studies to assist in defining the rubella susceptibility profile in school-aged girls and women of childbearing age. Information from such studies will be useful in the consideration of appropriate rubella control strategies in Ethiopia.
